CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models
Rita Sala, Hector Esquer, Timothy Kellett, Sophia Clune, Paul Awolade, Laura A Pike, Qiong Zhou, Wells A Messersmith, Daniel V LaBarbera, Carmine Stolfi · 2024
Read CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models by Rita Sala, Hector Esquer, Timothy Kellett, Sophia Clune, Paul Awolade, Laura A Pike, Qiong Zhou, Wells A Messersmith, Daniel V LaBarbera, Carmine Stolfi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641930.txt.
Description
Rita Sala and co-authors test in a 2024 study whether blocking a gene that helps cancers fix DNA damage makes bowel cancer drugs hit harder. The gene, CHD1L, is a driver that also steers harmful gene programs. Their blocker, OTI-611, was paired with the standard drug trio used against this cancer.
In cell lines the pair raised DNA damage sharply, and in tumor organoids the blocker boosted each drug's kill. It also trapped repair proteins on the DNA, tipping cells into a death path. In mice, low doses with one drug shrank tumors and stretched survival beyond the drug alone.
Catalog record
| CREATOR | Rita Sala, Hector Esquer, Timothy Kellett, Sophia Clune, Paul Awolade, Laura A Pike, Qiong Zhou, Wells A Messersmith, Daniel V LaBarbera, Carmine Stolfi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |